Massachusetts Medicaid (MassHealth) GLP-1 Coverage (2026): Pattern #15 — Two-Phase Termination Policy-Reversal (Jan 2024–Jun 2026 Positive Coverage Then Jul 1 2026 Chronic-Weight-Management Termination + MACE/MASH/OSA Phase 2 Carve-Outs + Healey Coordinated Retrenchment + 130 CMR 406.413(B) Anticipated-Forthcoming Procedural Anomaly)

Pattern #15 — Two-Phase Termination Policy-Reversal

Massachusetts is the 15th state analyzed in this 50-state Medicaid GLP-1 series and the second policy-reversal state after Pennsylvania (Anchor #7). The MA narrative has a unique structural feature that distinguishes it from every prior state: a two-phase termination arc in which Phase 1 (January 2024 – June 30, 2026) is a standard positive-coverage window and Phase 2 (July 1, 2026 onward) converges with Washington (Anchor #14) and Ohio (Anchor #6) on indication-anchored MACE/MASH/OSA coverage with an explicit chronic-weight-management exclusion.

Where MA sits relative to the 14 prior states:

• vs. Pennsylvania (#7) — the closest analog: Both are policy-reversal states. PA terminated after 34 months (January 1, 2026; 38-day notice via MAB2025112403 + existing 55 Pa. Code § 1121.54). MA terminates after 30 months (July 1, 2026; 110-day notice via Pharmacy Facts #271 + anticipated forthcoming 130 CMR 406.413(B) amendment). The procedural distinction: PA’s regulatory instrument was already in place; MA’s is still pending as of May 10, 2026. MA’s Phase 2 coverage is also broader than PA’s (MA: MACE BMI > 27 + MASH + OSA; PA: narrower carve-outs per MAB2025112403).
• vs. Washington (#14) — post-July 2026 convergence: WA has been indication-anchored since 2023–2024 (Wegovy MACE BMI ≥ 27; MASH F2/F3; Zepbound OSA AHI ≥ 15 per HCA Medical Policies 61.25.20.AA-4 and 61.25.25.AA-1). MA’s Phase 2 architecture is taxonomically equivalent to WA on all three indication dimensions. The structural difference: WA never had a positive-coverage window; MA is transitioning into WA’s architecture.
• vs. Tennessee (#13) — the 12-month inversion: TN added obesity coverage August 1, 2025 via Sequence 10-34-25 ($2.7M annual expenditure). MA terminates obesity coverage July 1, 2026 (~$15M annual savings). Opposite fiscal directions in the same calendar window. See the dedicated section below.
• vs. KFF taxonomy: KFF (January 16, 2026) does NOT classify MA as a positive-coverage state. This reflects KFF’s assessment of the narrowing trajectory, not an error — MA’s January 2025 narrowing and February 2026 BMI tightening placed it in an ambiguous coverage-pending-elimination status.

Phase 1 vs. Phase 2 — the two-phase timeline

MassHealth’s GLP-1 obesity coverage history has four operational milestones before the July 1, 2026 terminal date:

Phase 1 spans 30 months (January 2024 – June 30, 2026). This is one operational distinction from Pennsylvania (Anchor #7), whose Phase 1 spanned 34 months (March 2023 – December 31, 2025). Both states are the two longest-running chronic-weight-management coverage windows in the series to terminate due to fiscal pressure.

The “anticipated forthcoming” 130 CMR 406.413(B) — a procedurally unique announcement-before-regulation sequence

The single most procedurally distinctive feature of MA’s termination is that the operational announcement (Pharmacy Facts #271, March 12, 2026) preceded the underlying regulatory amendment to 130 CMR 406.413(B). The announcement quotes:

“In accordance with anticipated forthcoming changes to MassHealth regulations, 130 CMR 406.413(B), MassHealth will no longer cover drugs used for the treatment of obesity or overweight. Effective July 1, 2026, the drugs listed below in Table 1 will no longer be covered for MassHealth members, when used for weight loss.”

What 130 CMR 406.413(B) currently says (verified May 10, 2026): The regulation enumerates six drug-exclusion categories — cosmetic drugs, cough/cold medications, fertility drugs, less-than-effective drugs, experimental/investigational drugs, and sexual dysfunction drugs. Anti-obesity drugs are not yet enumerated in Section (B). The amendment is procedurally pending.

This is a distinct procedural pattern from both Pennsylvania and Tennessee:

• Pennsylvania (Anchor #7): MAB2025112403 (November 24, 2025) announced the January 1, 2026 termination. The regulatory anchor (55 Pa. Code § 1121.54) was already in place and needed no new promulgation — it provided the pre-existing exclusion authority. PA’s termination was operationally anchored in an existing regulation with a new operational bulletin layered on top.
• Tennessee (Anchor #13): Sequence 10-34-25 completed a full formal rulemaking process (July 14, 2025 notice; September 4, 2025 hearing; October 28, 2025 filing; January 26, 2026 permanent-rule effective date). The regulatory instrument and the operational deployment happened simultaneously.
• Massachusetts (Anchor #15): The operational bulletin (Pharmacy Facts #271) was issued March 12, 2026 announcing the July 1, 2026 effective date. The regulatory amendment (130 CMR 406.413(B)) has not yet been promulgated as of May 10, 2026. MassHealth is deploying the termination via the operational instrument while the regulatory instrument is being prepared.

The practical implication for members and providers: the July 1, 2026 termination is operationally binding under Pharmacy Facts #271 regardless of the regulatory amendment’s promulgation status. Providers should not assume the termination will be delayed because the CMR amendment has not yet appeared in the Code of Massachusetts Regulations.

The federal authority underlying the anticipated amendment is 42 U.S.C. § 1396r-8(d)(2)(A), which authorizes states to exclude “Agents when used for anorexia, weight loss, or weight gain” from Medicaid coverage. MA exercised discretion not to invoke this exclusion from January 2024 through June 30, 2026. The July 1, 2026 termination represents MA re-invoking this federal optional-exclusion authority — with carve-outs for MACE/MASH/OSA non-weight-loss indications preserved.

Pharmacy Facts #271 — the canonical termination announcement

The full verbatim termination paragraph from Pharmacy Facts Number 271 (March 12, 2026), page 1, lines 7–10:

“In accordance with anticipated forthcoming changes to MassHealth regulations, 130 CMR 406.413(B), MassHealth will no longer cover drugs used for the treatment of obesity or overweight. Effective July 1, 2026, the drugs listed below in Table 1 will no longer be covered for MassHealth members, when used for weight loss.”

Table 1 verbatim (lines 12–22):

“Table 1: Anti-Obesity Agents
benzphetamine
diethylpropion, diethylpropion extended-release
Saxenda (liraglutide)
Xenical (orlistat)
phendimetrazine, phendimetrazine extended-release
Lomaira, Adipex-P (phentermine capsule, tablet)
Wegovy (semaglutide)
Zepbound (tirzepatide)
*Any drug being used off-label for weight loss is not payable for MassHealth patients.”

The asterisked off-label footnote closes a loophole: after July 1, 2026, prescribers cannot route around the exclusion by submitting Ozempic (semaglutide) for obesity — Ozempic’s FDA label does not include obesity, and the off-label-weight-loss exclusion is explicit.

Three retained non-weight-loss indications (verbatim, lines 24–30):

“Weight loss glucagon-like peptide-1 (GLP-1) or GIP (glucose- dependent insulinotropic polypeptide)/GLP-1 medications will be covered beyond June 30, 2026, for members with approved prior authorizations (PAs) for other medically accepted indications including:
• Body Mass Index (BMI) >27 kg/m² and established cardiovascular disease to reduce the risk of major adverse cardiovascular events (MACE)
• Metabolic dysfunction-associated steatohepatitis (MASH)
• BMI >30 kg/m² and moderate to severe obstructive sleep apnea (OSA)”

Note: Pharmacy Facts #271 uses strict-inequality “>” for the MACE (BMI > 27) and OSA (BMI > 30) thresholds. The MHDL Anti-Obesity Agents page uses “≥”. The MHDL page (≥) is the operationally binding PA criteria document; Pharmacy Facts #271’s “>” is narrative shorthand. Members with exactly BMI = 27 (for MACE) or BMI = 30 (for OSA) should use the MHDL criteria as the authoritative source.

Phase 1 chronic-weight-management criteria — through June 30, 2026

Through June 30, 2026, the operative PA criteria are those published in Pharmacy Facts #269 (January 14, 2026) and reflected in the MHDL Anti-Obesity Agents page (effective 04/2026, updated 05/04/2026). Wegovy and Zepbound are covered at parity for adults ≥ 18 under three BMI-tiered eligibility ladders.

Verbatim from Pharmacy Facts #269, lines 27–41:

“Wegovy® (semaglutide) will be added as a preferred drug managed at parity with Zepbound® (tirzepatide) with new body mass index (BMI) and comorbidities eligibility criteria for adults.
a. Members with a BMI ≥ 35 kg/m²
b. Members with a BMI ≥ 30 to < 35 kg/m², and one of the following conditions:
 o Heart failure with preserved ejection fraction
 o Uncontrolled hypertension despite pharmacotherapy
 o Chronic kidney disease stage 3a or above
 o Moderate or severe obstructive sleep apnea
c. Members with a BMI ≥ 27 kg/m², and one of the following conditions:
 o Type 2 diabetes mellitus or prediabetes (member needs to use an antidiabetic GLP-1)
 o Prior myocardial infarction or stroke
 o Symptomatic peripheral artery disease
 o Metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis
• Please note: For members stable on a GLP-1, baseline BMI (defined as the BMI prior to starting an anti-obesity medication) is used to determine eligibility for continued treatment. Some members currently utilizing a weight-loss GLP-1 medication may no longer be eligible under these revised criteria and will be denied coverage at the time of recertification.
• Saxenda® (liraglutide) will continue to be covered with prior authorization for pediatric members ≥ 12 years of age. It requires a trial with Wegovy® (semaglutide), unless contraindicated.
• A phentermine trial will no longer be required before treatment with a weight loss GLP-1.”

T2DM in tier (c) requires members to use an antidiabetic GLP-1 (Ozempic, Mounjaro, Trulicity, or Victoza) rather than a weight-loss GLP-1. This is the operative steerage rule: a member with T2DM cannot use Wegovy or Zepbound for weight management via this tier — they must be directed to the antidiabetic PDL.

PA end-dating: per Pharmacy Facts #271, PAs submitted before February 17, 2026 will be end-dated for June 30, 2026 regardless of indication and must be resubmitted. PAs submitted for weight-loss indications between February 17 and June 30, 2026 will expire on June 30, 2026. Members with existing weight-loss PAs should be counseled that the approval is terminal.

Phase 2 indication-anchored carve-outs — after July 1, 2026

After July 1, 2026, Wegovy and Zepbound remain covered only for three non-weight-loss FDA indications. The PA resubmission deadline and documentation requirements are set in Pharmacy Facts #271 (verbatim, lines 50–55):

“Other Medically Accepted Indications:
 o Prior authorizations for MACE, MASH, or OSA will be reviewed, and approved for up to six months if all appropriate documentation is attached (e.g. apnea-hypopnea index (AHI) score for OSA and fibrosis stage for MASH).
 o If no documentation is attached certifying severity, PAs for MACE, MASH and OSA will be end-dated for June 30, 2026.”

MACE pathway: BMI ≥ 27 + established cardiovascular disease + appropriate diagnosis. The MHDL Wegovy MACE criteria require documentation of prior MI, prior stroke, or symptomatic peripheral artery disease (confirmed by chart notes). The prescriber must attest the member is not a candidate for an antidiabetic GLP-1 for the prediabetes sub-indication. MACE PA duration: up to 6 months per Pharmacy Facts #271.

MASH pathway: Noncirrhotic MASH with moderate-to-advanced fibrosis (F2/F3). Verbatim MHDL Wegovy MASH criteria:

“Documentation of the following is required for treatment of nonalcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH), with moderate to advanced liver fibrosis: appropriate diagnosis; and medical records from liver biopsy or noninvasive testing (NIT) supporting the diagnosis of NASH or MASH, with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis); and member is ≥ 18 years of age; and prescriber is a gastroenterologist or hepatologist or consult notes from a gastroenterologist or hepatologist are provided; and member has been counseled to continue reduced-calorie diet and increased physical activity; and member has been counseled to limit alcohol use; and requested quantity is ≤ four pens/28 days; and requested agent will not be used in combination with another GLP-1 receptor agonist.”

Acceptable NIT modalities include FibroScan (liver stiffness measurement), FIB-4 score, APRI, FibroTest, and MR elastography. Gastroenterologist or hepatologist involvement is mandatory — a primary-care-only submission will be denied.

OSA pathway: Zepbound only (no Wegovy OSA PA criteria are listed on the MHDL as of May 10, 2026). BMI ≥ 30 + moderate- to-severe OSA defined as AHI > 15 without central or mixed sleep apnea. The MHDL full PA criteria are structurally parallel to Zepbound for obesity (see Phase 1 criteria above), with the OSA documentation requirement substituting for the obesity-comorbidity documentation. Sleep study AHI documentation must be attached; per Pharmacy Facts #271, OSA PAs without attached AHI documentation will be end-dated June 30, 2026.

Diabetes/prediabetes transition pathway (verbatim, Pharmacy Facts #271, lines 47–49):

“Diabetes and Prediabetes: Approvable PAs will expire on June 30, 2026. For continued coverage beginning July 1, 2026, members should be switched to an antidiabetic GLP-1. Current MassHealth coverage of diabetic GLP-1s and GIP/GLP-1s is outlined in Table 2 below.”

Antidiabetic GLP-1 preferred drugs after July 1, 2026 (Pharmacy Facts #271, Table 2): Ozempic (semaglutide injection), Trulicity (dulaglutide), Victoza (liraglutide) (preferred); preferred GIP/GLP-1:Mounjaro (tirzepatide). Non-preferred: Bydureon Bcise (exenatide ER), exenatide, Rybelsus (semaglutide tablet). Members currently on Wegovy or Zepbound with a T2D or prediabetes indication should begin the antidiabetic PDL transition now.

The baseline BMI recertification rule — the most subtle YMYL trap in this cluster

Effective February 17, 2026, MassHealth changed how it evaluates eligibility at recertification. The MHDL Anti-Obesity Agents footnote states verbatim:

“*Effective February 17, 2026, for members stable on a weight loss GLP-1, comorbid conditions and baseline BMI (defined as the BMI prior to starting a GLP-1 medication) are used to determine eligibility for continued treatment. Some members currently utilizing a weight-loss GLP-1 medication may no longer be eligible under these revised criteria and will be denied coverage at the time of recertification.”

The practical consequence: a member who started Wegovy with abaseline BMI of 38 and dropped to a current BMI of 32 over 18 months of treatment is evaluated against BMI 38 (baseline) at recertification — not BMI 32 (current). The member remains eligible under tier (a) (BMI ≥ 35) because their pre-treatment BMI of 38 qualifies.

Without this rule, a member’s own therapeutic success — BMI dropping below 35 or below 30 during treatment — would paradoxically disqualify them from recertification under the standard current-BMI criteria. The baseline-BMI rule prevents this perverse outcome.

Why this is a YMYL trap: This rule is buried in a single MHDL footnote and is not highlighted in the main Phase 1 criteria body. Members who improve their BMI significantly during Phase 1 treatment may incorrectly assume they will not qualify for recertification — and may stop their medication prematurely. Providers should proactively document the member’s baseline BMI in the chart at the time of initiation so it is available for recertification reference.

Note: this rule applies to Phase 1 recertification (through June 30, 2026). After July 1, 2026, weight-loss-indication coverage terminates entirely for adults. The baseline-BMI rule will remain operationally relevant for members seeking the MACE, MASH, or OSA Phase 2 pathways only to the extent their Phase 2 eligibility criteria overlap with the recertification framework.

Tennessee mirror-image — the 12-month inversion

The Tennessee (Anchor #13) – Massachusetts (Anchor #15) pairing is the most direct case study in this 50-state series of how individual state fiscal policy and executive priorities drive opposite GLP-1 obesity coverage outcomes in the same calendar window:

• Tennessee: effective August 1, 2025 (emergency rule) and permanent effective January 26, 2026 (Sequence 10-34-25), TennCareadded obesity coverage from a prior categorical-exclusion baseline. Fiscal framing verbatim from the Sequence 10-34-25 fiscal note: anticipated to increase annual TennCare expenditures by approximately $2.7 million.
• Massachusetts: effective July 1, 2026 (Pharmacy Facts #271, March 12, 2026), MassHealth will terminate obesity coverage after 30 months of positive coverage. Fiscal framing: Healey administration projects ~$15 million in annual MassHealth savings.

The two states’ fiscal projections reflect the same underlying political economy: TN modeled a de minimis expenditure addition for a new population; MA modeled a significant savings extraction from an established covered population. The per-member-year cost in MA’s case is substantially higher because the covered population had been accruing for 30 months and includes members at higher medication doses.

In the same fiscal year in which TN began paying for Zepbound and Wegovy for ~$2.7M annually, MA decided the ~$15M annual cost of continuing coverage was no longer fiscally responsible. The 12-month gap between TN’s August 2025 expansion and MA’s July 2026 termination is the most compressed version of this inversion in the 50-state series to date.

Healey coordinated retrenchment — the most comprehensive state-level GLP-1 pullback in the series

The July 1, 2026 MassHealth termination is one instrument in a multi-program coordinated retrenchment under the Healey administration. Each instrument is documented separately:

1. Healey FY2027 budget (January 28, 2026): Filed a $63 billion budget with an administrative proposal to eliminate GLP-1 weight-loss coverage at MassHealth. Projected savings: ~$15 million annually. Per reporting: “Prescription drug spending at MassHealth increased by 18% from 2024 to 2025, with GLP-1 drugs accounting for under half of that growth.”
2. H.4251 Section 8 (July 4, 2025): Governor Healey filed H.4251 with Section 8 granting GIC mid-year plan-change authority (notwithstanding M.G.L. c. 32A Section 6). The filing letter stated verbatim: “We are also requesting limited authority to make mid-year health insurance plan changes for members to address extreme price volatility related to GLP-1 weight-loss drugs. This will allow us to save $27.5 million in FY26.” This provision targets GIC (state employees, M.G.L. c. 32A) — NOT MassHealth.
3. GIC February 26, 2026 vote (10-7): The Group Insurance Commission voted to terminate weight-loss GLP-1 coverage for state employees, exercising the H.4251 Section 8 authority. Verbatim (WBUR, February 26, 2026): “Some 22,000 GIC members currently take GLP-1 drugs for weight loss, at a total cost of $46 million.” GIC covers 460,000 public employees and retirees (M.G.L. c. 32A). This is a GIC event, NOT a MassHealth event.
4. Pharmacy Facts #271 MassHealth termination (March 12, 2026): Operational announcement of the July 1, 2026 MassHealth exclusion under anticipated 130 CMR 406.413(B) amendment. This is the MassHealth (M.G.L. c. 118E / 130 CMR) instrument — separate from GIC.
5. Health Safety Net (HSN) termination (April 15, 2025): Pharmacy Facts #244 documented HSN’s termination of anti-obesity coverage 15 months before MassHealth’s parallel termination. Verbatim: “In accordance with Health Safety Net (HSN) regulations at 101 CMR 613.03(2)(e), the HSN does not pay for drugs used for the treatment of obesity.” HSN is NOT MassHealth — it is a separate state-funded program for low-income uninsured/underinsured residents who do not qualify for MassHealth.
6. Filing Guidance Notice 2025-H (March 4, 2025): The Division of Insurance (DOI) issued guidance allowing commercial health insurance carriers in Massachusetts to scale back CY2026 GLP-1 weight-loss coverage, provided member notification requirements are met. FGN 2025-H is anchored in M.G.L. c. 176O and applies to commercial fully-insured carriers — NOT MassHealth. This is cited here only as a documented component of the coordinated retrenchment picture; it is entirely separate from MassHealth’s regulatory authority.

Taken together, these six instruments represent the most comprehensive documented state-level GLP-1 retrenchment in this 50-state series — spanning the state employee plan, Medicaid, a separate safety-net program, and commercial insurance guidance, all coordinated within a 14-month window (January 2025 to March 2026). The article frames this as a documented historical record of the Healey administration’s fiscal priorities; no political motive is imputed.

Legislative non-action: Both the House Ways & Means budget (April 15, 2026) and the Senate Ways & Means budget (May 6, 2026) declined to block the July 1, 2026 MassHealth elimination. As of May 10, 2026, the FY2027 budget process is ongoing — the July 1, 2026 implementation date should be treated as scheduled subject to final budget passage and any legislative action on the 130 CMR 406.413(B) regulatory amendment.

Amendment #7 to H.4530 (Soter, withdrawn) — a failed pro-coverage GIC reform attempt

Representative Michael J. Soter of Bellingham (with nine co-sponsors) filed Amendment #7 to H.4530, proposing to add Section 17T to Chapter 32A of the General Laws — a new GIC provision mandating GLP-1 coverage. Verbatim from the amendment:

“Section 17T. Coverage for GLP-1 Medications. (a) Any coverage offered by the commission to an active or retired employee of the commonwealth insured under the group insurance commission shall provide coverage for glucagon-like peptide-1 receptor agonist medications (GLP-1s) that have been approved by the United States Food and Drug Administration for: (i) treatment of diabetes; (ii) chronic weight management or obesity; or (iii) any other indication for which such medication has received FDA approval. (b) Such coverage shall not be restricted to circumstances of ‘medical necessity’ narrower than the FDA-approved indications, nor shall coverage be eliminated or reduced by mid-year plan design changes.”

Subsection (b) would have directly prohibited mid-year plan-design changes eliminating GLP-1 coverage — a direct counter to H.4251 Section 8. The amendment proposed a $27.5 million appropriation to GIC to fund the coverage mandate. STATUS: WITHDRAWN. Section 17T was not enacted into Chapter 32A. The amendment targeted GIC (NOT MassHealth) — it would not have affected the July 1, 2026 MassHealth termination even if it had passed.

The reason for the withdrawal was not extracted in the primary-source verification session for this article and should not be speculated upon. The empirical record is that the amendment was filed and withdrawn. Future re-filing is a legislative matter not predictable from available primary sources.

PBM architecture — Conduent (MHDL), UMass Chan ForHealth, and the DUR program

MassHealth’s pharmacy benefit operates through a unified platform rather than a traditional single-PBM structure:

• Conduent: The MHDL platform vendor. mhdl.pharmacy.services.conduent.com is the public-facing URL for all PA criteria, drug list lookups, and formulary management. Conduent hosts and operates the MHDL but is the platform vendor, not the clinical authority.
• University of Massachusetts Chan Medical School ForHealth Consulting: The clinical analysis contractor. The UMass Chan ForHealth / MassHealth Drug Utilization Review (DUR) Program reviews drug class management decisions, PA criteria design, and pharmacoeconomic analysis. Analogous to OptumRx in TennCare, Acentra in Texas, and Magellan in California.
• MassHealth Pharmacy Program: The administrative authority. Issues Pharmacy Facts bulletins, Prescriber e-Letters, and formal PA criteria. All primary-source MHDL and Pharmacy Facts documents originate from the MassHealth Pharmacy Program.
• Unified formulary architecture: Per Pharmacy Facts #159 (December 31, 2020, the ACPP/MCO Unified Pharmacy Product List anchor), the MHDL applies uniformly to MassHealth fee-for-service, all ACO products (MGB, Tufts Health Together, Fallon, the WellSense cluster), the two Primary Care ACOs (Community Care Cooperative C3, Revere Health Choice), and the WellSense Essential MCO. Switching between MassHealth plans will not change GLP-1 PA criteria. The limited exception is drugs marked “MB” (medical benefit, administered via J-code / B-code billing) where individual ACPPs/MCOs may apply distinct PA criteria within the medical pathway.

GIC vs. MassHealth — a mandatory YMYL distinction

This article covers MassHealth (Medicaid) only. GIC coverage decisions are entirely out of scope.

T2D vs. weight-loss coverage — a common source of confusion

The July 1, 2026 termination applies only to GLP-1 agents prescribed for chronic weight management, overweight, or obesity. T2D-indicated GLP-1s are unaffected. The following preferred drugs continue to be covered for T2D with prior authorization after July 1, 2026 (per Pharmacy Facts #271, Table 2):

• Preferred (T2D): Ozempic (semaglutide injection), Trulicity (dulaglutide), Victoza (liraglutide)
• Preferred GIP/GLP-1 (T2D): Mounjaro (tirzepatide)
• Non-preferred (T2D): Bydureon Bcise (exenatide ER), exenatide, Rybelsus (semaglutide tablet)

A member whose provider submits Wegovy or Zepbound under a T2D PA after July 1, 2026 will be denied — Wegovy and Zepbound are weight-loss agents; the T2D pathway requires the antidiabetic PDL agents listed above. The off-label footnote in Pharmacy Facts #271 (Table 1) closes any attempt to route Ozempic for obesity through an off-label weight-loss submission.

Comparison with the 14 prior states

MA’s Phase 2 architecture is broader than PA’s on OSA (PA requires BMI ≥ 35 for OSA; MA requires BMI ≥ 30) and equivalent to WA on all three dimensions. MA is broader than NY on every indicator (NY: MACE BMI ≥ 40 + 2-attempt cap; MA: MACE BMI ≥ 27 + no attempt cap; NY: no MASH or OSA; MA: both). MA is broader than CA post-reversal (CA: MASH only; MA: MACE + MASH + OSA). IL, GA, TX, FL, and AZ have no verified MACE/MASH/OSA carve-outs — MA is broader on all three indications after July 1, 2026.

Excluded populations and program scope

This article covers MassHealth (Medicaid) fee-for-service and ACO/MCO managed care only. The following populations and programs are out of scope:

• GIC (state-employee plan): Governed by M.G.L. c. 32A. Separate program. Coverage decisions are not MassHealth decisions.
• Health Safety Net (HSN): A separate state-funded program for low-income uninsured/underinsured residents who do not qualify for MassHealth. HSN terminated anti-obesity coverage April 15, 2025 (per Pharmacy Facts #244). Not MassHealth.
• Dual-eligible beneficiaries (Medicare + MassHealth): Approximately 300,000 Massachusetts residents have both Medicare and MassHealth. Their GLP-1 coverage is governed by Medicare Part D rules. Medicare Part D added Wegovy for MACE in 2024 and for MASH in August 2025. Dual-eligible specifics were not verified in this article.
• Commonwealth ConnectorCare / ACA marketplace plans: Massachusetts operates the Health Connector for ACA marketplace plans. Commercial and marketplace GLP-1 coverage is governed by M.G.L. c. 176O and FGN 2025-H (DOI), not MassHealth.
• CoverAll Kids / CHIP: Massachusetts’s CHIP program has different formulary rules. CHIP specifics are not addressed in Pharmacy Facts #271.
• EPSDT-eligible members (under 21): Expresslyin scope for continued coverage after July 1, 2026 under 42 U.S.C. § 1396d(r) and 130 CMR 406.413(C). These members retain coverage when medically necessary; they are not excluded from Phase 2 access.

Patient action steps before July 1, 2026

1. Confirm your current PA status. Per Pharmacy Facts #271, all PAs for anti-obesity agents submitted before February 17, 2026 will be end-dated June 30, 2026 regardless of indication. Call MassHealth Member Services to confirm your PA end date.
2. Identify whether you qualify for Phase 2 coverage. If you have established cardiovascular disease (prior MI, stroke, or symptomatic PAD) with BMI ≥ 27, OR a MASH diagnosis with F2/F3 fibrosis confirmed by biopsy or NIT, OR documented moderate-to-severe OSA with AHI ≥ 15 and BMI ≥ 30, begin gathering the documentation now. Do not wait until after June 30, 2026.
3. Gather OSA documentation if applicable. The sleep-study AHI score is mandatory for the OSA PA. Per Pharmacy Facts #271: “If no documentation is attached certifying severity, PAs for MACE, MASH and OSA will be end-dated for June 30, 2026.”
4. Gather MASH documentation if applicable. Liver biopsy or NIT results (FibroScan, FIB-4, APRI, FibroTest, MR elastography) confirming F2 or F3 fibrosis staging. Arrange gastroenterologist or hepatologist involvement before submitting the Phase 2 PA.
5. If you have T2D: Your provider should begin the transition to an antidiabetic GLP-1 (Ozempic, Mounjaro, Trulicity, or Victoza) now. Per Pharmacy Facts #271: “Approvable PAs will expire on June 30, 2026. For continued coverage beginning July 1, 2026, members should be switched to an antidiabetic GLP-1.”
6. Recertification baseline BMI. If you are currently on a weight-loss GLP-1, confirm with your provider that your baseline BMI (pre-treatment) is documented in your chart. This protects your Phase 1 recertification eligibility through June 30, 2026.
7. Cash-pay bridge options during Phase 2 transition: NovoCare offers Wegovy savings cards; LillyDirect offers Zepbound vials at $299–$449/month; Foundayo (oral orforglipron, not a MassHealth covered agent) is available at LillyDirect for ~$149/month.

Appeal pathway — MassHealth Office of Medicaid Board of Hearings

Adverse benefit determinations are appealed to the Office of Medicaid Board of Hearings (BOH), governed by 130 CMR 610.000 (“MassHealth: Fair Hearing Rules”). Per 130 CMR 610.015, the filing deadline is:

Members must request a fair hearing within 30 days after receiving written notice of the adverse benefit determination. This is shorter than TennCare’s 60-day window and most other states in this series.

Key appeal logistics:

• Standard expedited: Expedited hearings for elective hospital admission denials are scheduled within 7 days of the BOH receiving the request, with a final decision within 7 days of the hearing.
• Starting after July 1, 2026: Denials for chronic weight-management-indication GLP-1s cannot be appealed as adjudication-error cases — the termination will be the operative policy rule. Appeals after July 1, 2026 should focus on whether the member’s indication is accurately classified (e.g., a member with documented MACE criteria who received a weight-loss-only denial may have grounds for an adjudication-error appeal).
• Aid-pending-appeal: Under MassHealth fair-hearing rules, timely appeals may preserve continuation of services pending resolution for ongoing services. Contact the BOH for specific instructions on continuation requests.

PA approval is not guaranteed regardless of BMI or diagnosis. This article documents the published criteria; individual PA decisions depend on case-specific medical documentation and MassHealth clinical review. This article does not constitute medical or legal advice.

Related research

• Pennsylvania Medicaid GLP-1 coverage (2026): the policy reversal — the closest analog to MA in this series. Both are policy-reversal states. PA terminated 34 months of coverage January 1, 2026; MA terminates 30 months July 1, 2026. Key procedural distinction: PA’s 55 Pa. Code § 1121.54 was already in place; MA’s 130 CMR 406.413(B) amendment is still forthcoming.
• Tennessee Medicaid GLP-1 coverage (2026): positive-coverage expansion — the 12-month inversion mirror. TN added obesity coverage August 1, 2025 via Sequence 10-34-25 ($2.7M annual expenditure). MA terminates obesity coverage July 1, 2026 (~$15M annual savings). Opposite fiscal directions in the same calendar window.
• Washington Apple Health (Medicaid) GLP-1 coverage (2026): the YMYL indication-anchored pattern — MA’s Phase 2 coverage architecture converges nearly exactly with WA on all three indication dimensions (MACE BMI ≥ 27, MASH F2/F3, Zepbound OSA AHI ≥ 15). WA has been indication-anchored continuously since 2023–2024; MA is transitioning into this architecture effective July 1, 2026.
• GLP-1 insurance dropped coverage appeal playbook — four-phase appeal logic including Medicaid fair-hearing guidance; MA’s 30-day BOH window (vs. most states’ 60 days) makes early action especially important.
• State Medicaid GLP-1 coverage hub — all 15 states analyzed to date with per-state taxonomy, coverage patterns, and last-verified dates.

Last verified: May 10, 2026. Primary sources: Pharmacy Facts Number 271 (March 12, 2026); Pharmacy Facts Number 269 (January 14, 2026); MassHealth Prescriber e-Letter Volume 14, Issue 3 (October 2024); MassHealth Drug List Anti-Obesity Agents page (Conduent, updated 05/04/2026, effective 04/2026); 130 CMR 406.413 (verified via Cornell LII May 10, 2026; amendment anticipated forthcoming); 42 U.S.C. § 1396r-8(d)(2)(A); Pharmacy Facts Number 244 (April 1, 2025); H.4251 (filed July 4, 2025); Amendment #7 to H.4530 (STATUS: WITHDRAWN); WBUR February 26, 2026 GIC vote reporting; mass.gov ACO/MCO list; Healey FY2027 budget reporting (WBUR, Boston Globe, statehousenews.com, January 28 – May 10, 2026); KFF Medicaid GLP-1 tracker (January 16, 2026); Filing Guidance Notice 2025-H (March 4, 2025). MassHealth Pharmacy Facts and MHDL criteria are subject to revision. Confirm with MassHealth Member Services before making clinical or financial decisions.